IP Library Patent Application 13621552
Patent Application
App. No. 13/621,552

Salivary Bioassay for Early Detection of Bone Loss

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/621,552
Abstract

The present invention is directed to methods to detect and diagnose osteoporosis and periodontal disease using salivary biomarkers.

Claims (16)

1 . A kit for detecting early-stage periodontal bone loss comprising a reagent that indicates the presence of a biomarker in a bodily fluid of a patient at a level that indicates early-stage periodontal bone loss and a device for contacting the bodily fluid with the biomarker.

2 . The kit of claim 1 , further comprising instructions that explains that the presence of the biomarker at the level indicates early-stage periodontal bone loss.

3 . The kit of claim 1 , wherein the bodily fluid is saliva.

4 . The kit of claim 1 , wherein the biomarker is selected from the group consisting of osteocalcin, RANK L, soluble RANKL, osteoprotegrin, alkaline phosphatase MIP 1α. 1,25 dihyroxy Vitamin D, 25-Hydroxy Vitamin D, TRAP 5b, TRACP 5b, deoxypyridinoline, FGF-23, PTH, MMP 8, MMP 13, and alpha CTX-I.

5 . The kit if claim 1 , wherein the level is greater than about 200 pg/ml.

6 . The kit if claim 1 , wherein the level is greater than about 400 pg/ml.

7 . The kit if claim 1 , wherein the level is greater than about 600 pg/ml.

8 . The kit if claim 1 , wherein the reagent is a fluorophore.

9 . A kit for detecting osteoporosis comprising a reagent that indicates the presence of a biomarker in a bodily fluid of a patient at a level that indicates osteoporosis and a device for contacting the bodily fluid with the biomarker.

10 . The kit of claim 9 , further comprising instructions that explains that the presence of the biomarker at the level indicates osteoporosis

11 . The kit of claim 9 , wherein the bodily fluid is saliva.

12 . The kit of claim 9 , wherein the biomarker is selected from the group consisting of osteocalcin, RANK L, soluble RANKL, osteoprotegrin, alkaline phosphatase MIP 1α. 1,25 dihyroxy Vitamin D, 25-Hydroxy Vitamin D, TRAP 5b, TRACP 5b, deoxypyridinoline, FGF-23, PTH, MMP 8, MMP 13, and alpha CTX-I.

13 . The kit if claim 9 , wherein the level is greater than about 200 pg/ml.

14 . The kit if claim 9 , wherein the level is greater than about 400 pg/ml.

15 . The kit if claim 9 , wherein the level is greater than about 600 pg/ml.

16 . The kit if claim 9 , wherein the reagent is a fluorophore.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 27, 2021
From: RUTGERS, THE STATE UNIV OF NJ
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 056992/0805 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 5, 2013
From: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 031170/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2012
From: FINE, DANIEL H.; FURGANG, DAVID
To: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Reel/Frame 029428/0884 →